Evelo Biosciences, Inc. Common Stock
EVLO
EVLO was delisted on the 11th of December, 2023.
2 hedge funds and large institutions have $2.63K invested in Evelo Biosciences, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 29 closing their positions.
93% less funds holding
Funds holding: 29 → 2 (-27)
93% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 29
100% less capital invested
Capital invested by funds: $52M → $2.63K (-$52M)
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$53.2K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$11.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
-$31.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.59M |
| 3 |
HP
Harbourvest Partners
Boston,
Massachusetts
|
-$5.69M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.4M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.04M |
EVLO Hedge Fund Activity: Q4 2023 in Review
2 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Evelo Biosciences, Inc. Common Stock (EVLO) for Q4 2023, worth a combined $2.63K — down 100% from $52M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of EVLO and 2 opened new positions — a net loss of 27 holders — while 0 trimmed existing stakes and 0 added.
The largest buyer was Acadian Asset Management, opening a new position worth an estimated $53.2K. The largest seller was Flagship Pioneering, exiting entirely with an estimated $31.1M sold.
- 2 institutional investors held Evelo Biosciences, Inc. Common Stock (EVLO) as of Q4 2023, down from 29 in Q3 2023.
- Funds reported $2.63K of Evelo Biosciences, Inc. Common Stock stock for Q4 2023, down 100% quarter-over-quarter.
- 2 funds opened new Evelo Biosciences, Inc. Common Stock positions in Q4 2023 and 29 closed out, a net change of -27 holders.
- The largest Evelo Biosciences, Inc. Common Stock buyer in Q4 2023 was Acadian Asset Management, an estimated $53.2K added.
- The largest Evelo Biosciences, Inc. Common Stock seller in Q4 2023 was Flagship Pioneering, an estimated $31.1M sold.
Based on aggregated 13F filings for Q4 2023.